{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:21:19Z","timestamp":1787757679002,"version":"build-2784847793"},"reference-count":39,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis Care &amp;amp; Research"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>We assessed the effectiveness of PrismRA to improve clinical outcomes among patients with rheumatoid arthritis (RA) initiating treatment with a biologic or targeted synthetic disease\u2010modifying antirheumatic drug (b\/tsDMARD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PrismRA incorporated 19 gene expression features and four clinical features to assess a patient's likelihood of inadequate response to tumor necrosis factor inhibitor (TNFi). PrismRA was assessed in a prospective, interventional cohort study of patients initiating treatment with a b\/tsDMARD. PrismRA results were provided to treating rheumatologists and incorporated into the selection of TNFi vs non\u2010TNFi for study treatment. External comparator patients were identified in a rheumatology provider electronic health records system and matched to PrismRA patients using propensity scores. All patients had moderate\u2010high disease activity at baseline. The primary study outcome was achievement of minimal important difference (MID) in clinical disease activity index (CDAI) at 24 weeks. Last observation carried forward was used to impute missing data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>There were 330 PrismRA cohort patients and 990 matched comparator patients. Key baseline patient characteristics were all well\u2010balanced between cohorts. Study treatment selection was consistent with PrismRA results in 82% of PrismRA cohort patients. CDAI MID at 24 weeks was achieved by 63.0% of PrismRA patients and 42.4% of comparator patients (odds ratio 2.31, confidence interval 1.79\u20132.99).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PrismRA results informing selection of TNFi vs non\u2010TNFi treatment was associated with better CDAI outcomes compared to matched external comparator patients. PrismRA testing helps fill the need for a precision medicine approach to more rapidly identify the most effective therapy for individual patients with RA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/acr.80010","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T10:17:59Z","timestamp":1769077079000},"page":"1149-1158","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Use of a Molecular Signature Response Classifier to Inform Treatment Selection Improves Clinical Disease Activity Among Patients with Rheumatoid Arthritis Initiating a Biologic or Targeted Synthetic Disease\u2010Modifying Antirheumatic Drug"],"prefix":"10.1002","volume":"78","author":[{"given":"Fenglong","family":"Xie","sequence":"first","affiliation":[{"name":"Foundation for Advancing Science, Technology, Education and Research  Birmingham Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Beukelman","sequence":"additional","affiliation":[{"name":"Foundation for Advancing Science, Technology, Education and Research  Birmingham Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas P.","family":"McCormick","sequence":"additional","affiliation":[{"name":"Foundation for Advancing Science, Technology, Education and Research  Birmingham Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8907-8976","authenticated-orcid":false,"given":"Jeffrey R.","family":"Curtis","sequence":"additional","affiliation":[{"name":"Foundation for Advancing Science, Technology, Education and Research  Birmingham Alabama"},{"name":"University of Alabama at Birmingham  Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41752"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223356"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-017-1366-1"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2010.03.003"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.210688"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2014.893241"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.2147\/OARRR.S372610"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-020-04746-7"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-021-00330-y"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380602"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737159.2021.2000394"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2022.2066972"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.70067"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-023-00618-1"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737159.2022.2140586"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737159.2022.2020648"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.27584"},{"issue":"5","key":"e_1_2_8_19_1","first-page":"S100","article-title":"The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis","volume":"23","author":"Aletaha D","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S242097"},{"key":"e_1_2_8_21_1","unstructured":"US Food and Drug Administration.Considerations for the design and conduct of externally controlled trials for drug and biological products.February 2023.https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/considerations\u2010design\u2010and\u2010conduct\u2010externally\u2010controlled\u2010trials\u2010drug\u2010and\u2010biological\u2010products"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3697"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2007.06.002"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X09341755"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(00)00321-8"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwy049"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/0962280210394483"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1214\/09-STS313"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/pst.433"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/00031305.1985.10479383"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwq224"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1080\/00273171.2011.568786"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22606"},{"issue":"2","key":"e_1_2_8_34_1","first-page":"280","article-title":"Determining the minimal clinically important differences in activity, fatigue, and sleep quality in patients with rheumatoid arthritis","volume":"34","author":"Wells G","year":"2007","journal-title":"J Rheumatol"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.180153"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpain.2003.09.004"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/aew466"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24253"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41927-023-00329-8"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217209"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.80010","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/acr.80010","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.80010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:49:24Z","timestamp":1787755764000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr.80010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1002\/acr.80010"],"URL":"https:\/\/doi.org\/10.1002\/acr.80010","archive":["Portico"],"relation":{},"ISSN":["2151-464X","2151-4658"],"issn-type":[{"value":"2151-464X","type":"print"},{"value":"2151-4658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]},"assertion":[{"value":"2025-06-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}